...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 in combination with "enzalutamide" in patients with metastatic castration resistant prostate cancer (mCRPC)
Reply New Message
Prev Message Back To Forum Threaded View Next Message

 Fascinating very quick look at ESSA.

  • Traded at $62.40 in Mar 2017
  • Dropped to $2.11 in Dec 2018
  • Up to $28.17 by July 2021
  • Down to $8.06 today

ZAKS points to lack of management communication for the drop. Sound familiar?

Fully diluted float = 56.1 million shares

Money in the bank on June 30 2021 = $202.3 million

ZAK's valuation - $40/share on early stage shakey results!

Oh where, oh where is our Donny-do-little hiding? ZCC should be thinking big....real BIG!

Cheers

Toinv         :)

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply